Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Day One Biopharmaceuticals (DAWN) EBT (2023 - 2025)

Historic EBT for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to -$19.7 million.

  • Day One Biopharmaceuticals' EBT fell 15633.05% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$145.2 million, marking a year-over-year increase of 2465.69%. This contributed to the annual value of -$197.6 million for FY2024, which is 460.19% down from last year.
  • Day One Biopharmaceuticals' EBT amounted to -$19.7 million in Q3 2025, which was down 15633.05% from -$30.3 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' EBT peaked at $35.0 million during Q3 2024, and registered a low of -$110.8 million during Q2 2024.
  • Over the past 3 years, Day One Biopharmaceuticals' median EBT value was -$46.0 million (recorded in 2023), while the average stood at -$43.0 million.
  • As far as peak fluctuations go, Day One Biopharmaceuticals' EBT skyrocketed by 17575.36% in 2024, and later tumbled by 15633.05% in 2025.
  • Quarter analysis of 3 years shows Day One Biopharmaceuticals' EBT stood at -$54.5 million in 2023, then fell by 8.78% to -$59.3 million in 2024, then skyrocketed by 66.78% to -$19.7 million in 2025.
  • Its EBT stands at -$19.7 million for Q3 2025, versus -$30.3 million for Q2 2025 and -$36.0 million for Q1 2025.